Hence, CKD-581 was effective regardless of CD20 and/or BCL-XL expression, and would be a candidate for clinical treatment of lymphoma, especially refractory/relapsed lymphoma after rituximab-based therapy. Here, BCL2L1 is linked to lymphoma.